Copyright © 2026 Knight Sac Media. All rights reserved.https://www.siliconinvestor.com/subject.aspx?subjectid=8617 I've researched these guys quite a bit and can't find anything bad except that it's a BORING business (however, you know what Peter Lynch says about boring businesses) Anyway, anbody else know anything? Dow Jones obviously sees something. check out the article, it gets better at the end NEW YORK (Dow Jones)--In January 1995, with $29,000 in sales to its credit from the previous year, Agribiotech Inc. (ABTX) went after its first acquisition - an Arizona company with $8 million in annual sales. ''They laughed at me and threw me out,'' President and Chief Executive Johnny Thomas told Dow Jones. But six months later, when Agribiotech had completed three other acquisitions, ''they called asking if we would buy the company.'' Just as that Arizona company had underestimated Agribiotech's financial strength and determination, the market undervalues the Las Vegas forage and turf seed concern because it doesn't understand how the company operates, Thomas said. But that should change in fiscal 1997, Thomas said, when the company expects to finally post a profit, become vertically integrated and move to the Nasdaq National Market from the SmallCap Market. Agribiotech has pursued an aggressive acquisition strategy, swallowing up 10 regional seed companies with operations in such states as Texas, Kentucky, Indiana and New York. Seven acquisitions alone were made in 1996, with those companies having total annual sales of $24 million, Thomas said. Mom-and-pop seed companies, with aging owners who don't have family to take over the businesses, have been Agribiotech's main targets in this fragmented industry, Thomas said. Corporate owners seeking to get out of forage and turf products to focus on higher-margin corn seed, have also been sellers, said Agribiotech Director John Francis. Forage seeds, primarily alfalfa, are sold to livestock and dairy producers. Turf grass is the kind found at parks and golf courses. The companies' depreciated assets are purchased at close to book value for a combination of cash and stock. The strategy has been a boon to sales, with revenue expected to rise in fiscal 1996 to $25.8 million, Thomas said, compared with $4.7 million reported last year, when the company switched to a year ending in June from September. Revenue could increase to $52 million in fiscal 1997, Thomas said, adding that sales might reach $80 million with additional acquisitions. He said he has a goal for fiscal 1997 of purchasing seed companies with total sales of $60 million. The losses Agribiotech has racked up should end in fiscal 1997, said Thomas. He predicted that net income as a percentage of revenues will be 1% to 5%, rising to 19.5% in five years. The synergies from previous acquisitions plus the completion of its largest purchase...https://www.siliconinvestor.com/images/Logo380x132.pnghttps://www.siliconinvestor.com/subject.aspx?subjectid=861738013210